About Amber Implants
We are an innovative and ambitious med-tech company that is working tirelessly to improve the quality of life for patients suffering from a variety of vertebral fractures.
Our Story
The story of Amber Implants began at Delft University of Technology, where founders Dr. Banafsheh Sajadi and Dr. Mohammad Ahmadi completed their Ph.D. studies and began translating advanced engineering concepts into innovative orthopaedic implant designs.
What started as a shared vision for better implant solutions has grown into a medical technology company focused on advancing spine care through minimally invasive reconstruction and stabilization technologies. Today, Amber Implants is supported by a rapidly growing team of engineers, clinicians, regulatory specialists, and commercialization leaders working together to bring meaningful innovation to vertebral fracture treatment.
As the company moves toward broader commercialization, Amber Implants continues to build on its scientific foundation, entrepreneurial spirit, and commitment to quality. The company operates in accordance with ISO 13485 and FDA guidelines for medical device development and manufacturing.
Our Mission
Quality
To relentlessly advance the treatment of vertebral fractures by delivering innovative, high-quality medical technologies that improve patient outcomes, restore function, and elevate quality of life.
Commitment
Amber Implants is committed to and accountable for advancing diversity, equity, and inclusion in all its forms.
Team
At Amber Implants, we strive for a healthy, inclusive, and high-performing organization where talented people are empowered to contribute to meaningful innovation in spine care.
Our team
Interested in joining our team? Check our available positions or submit your application by clicking the button below.
Company Timeline
Company launches and receives seed funding.
Company expands its research footprint by participating in multiple European and national research initiatives and collaborating with 20 partners in support of orthopaedic implant development.
VCFix® advanced through early feasibility work and project planning, establishing the foundation for subsequent product development and regulatory engagement.
VCFix® Spinal System receives Breakthrough Device Designation from the U.S. FDA, supporting priority review during development.
Company receives Series A funds.
Company finishes pre-clinical activities and regulatory phase.

Company successfully completes the First-in-Human clinical trials, including follow-up. For more information, see news item.

Company receives approval from both the Ethics Committee (EC) and BfArM in Germany for pivotal EXPAND study of the VCFix® Spinal System.

Introduction of VCFix® Spinal System with cement in the US market.


